Key result
CRT upgrade linked to improved HF symptoms and LV function across etiologies over ~59 months.
Why the study?
CRT upgrade procedures have shown controversial results, and long-term outcomes regarding underlying ischaemic versus non-ischaemic heart disease had not yet been described.
Does upgrade to CRT improve heart failure symptoms and left-ventricular systolic function in patients with chronic heart failure, and do outcomes differ between ischaemic versus non-ischaemic heart disease?
Observational (n=52)
Does upgrade to CRT improve heart failure symptoms and left-ventricular systolic function in patients with chronic heart failure, and do outcomes differ between ischaemic versus non-ischaemic heart disease?
Upgrading to CRT provides long-term improvements in heart failure symptoms and systolic function regardless of whether the underlying etiology is ischemic or non-ischemic.
Supports CRT upgrade consideration in chronic HF across etiologies; leaves open need for randomized confirmation of long-term effects.
BACKGROUND: Cardiac resynchronisation therapy (CRT) can be necessary in patients with chronic heart failure, who have already been provided with transvenous cardiac implantable electrical devices. Upgrade procedures revealed controversial results, while long-term outcomes regarding underlying Ischaemic- (ICM) or Non-Ischaemic heart disease (NICM) have yet to be described. METHODS: = 52) and compared for New York Heart Association classification (NYHA), paced QRS-width, left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE) and other heart failure modification aspects in the long-term (59.3 ± 5 months). CONCLUSIONS: Upgrade to CRT might improve heart failure symptoms and left-ventricular systolic function in the long-term, irrespective of underlying ischaemic or non-ischaemic heart disease.
No takes yet. Share an insight, caveat, or question.
Yuecel et al. (2023) conducted an observational in Chronic heart failure (n=52). Upgrade to cardiac resynchronisation therapy (CRT) vs. Ischaemic vs Non-Ischaemic heart disease was evaluated on New York Heart Association classification (NYHA), paced QRS-width, LVEF, and TAPSE (p=<.05). Upgrade to cardiac resynchronisation therapy improved heart failure symptoms and left-ventricular systolic function over 59.3 months, irrespective of ischaemic or non-ischaemic etiology (P<.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: